Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: Results from the phase 2 CheckMate 9KD trial

Karim Fizazi*, Margitta Retz, Daniel P. Petrylak, Jeffrey C. Goh, Jose Perez-Gracia, Louis Lacombe, Stefanie Zschäbitz, Mauricio Burotto, Hakim Mahammedi, Gwenaelle Gravis, Diogo Assed Bastos, Steven L. McCune, Juan Carlos Vázquez Limón, Edmond M. Kwan, Daniel Castellano, Aude Fléchon, Fred Saad, Marc Oliver Grimm, David R. Shaffer, Andrew J. ArmstrongPrabhu Bhagavatheeswaran, Neha P. Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Jun Li, Andrea Loehr, Russell K. Pachynski

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Fingerprint

Dive into the research topics of 'Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: Results from the phase 2 CheckMate 9KD trial'. Together they form a unique fingerprint.

Medicine & Life Sciences